Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 4, 2007, Pages 237-243

  Kanthou, Chryso ^a   Tozer, Gillian M ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ADH 1; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AZIXA; BCN 105; BEVACIZUMAB; CARBOPLATIN; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; CYT 997; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOFLAXONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MPC 6827; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NPI 2358; PACLITAXEL; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ZYBRESTAT;

ANAPLASTIC CARCINOMA; ANTIANGIOGENIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CYTOKINE RELEASE; CYTOSKELETON; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HEART MUSCLE ISCHEMIA; HUMAN; LUNG NON SMALL CELL CANCER; NEUROLOGIC DISEASE; NONHUMAN; RADIOIMMUNOTHERAPY; REVIEW; SLURRED SPEECH; THYROID CANCER; TREMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VISUAL DISORDER;

EID: 46749126105     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.03.003     Document Type: Review

References (66)

1. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer 45 (1982) 136-139
2. Denekamp J., et al. Vascular occlusion and tumour cell death. Eur. J. Cancer Clin. Oncl. 19 (1983) 271-275
3. Tozer G.M., et al. Disrupting tumour blood vessels. Nat. Rev. Cancer 5 (2005) 423-435
4. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10 (2004) 415-427
5. Neri D., and Bicknell R. Tumour vascular targeting. Nat. Rev. Cancer 5 (2005) 436-446
6. Jordan A.M., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-264
7. Mariotti A., et al. N-cadherin as a therapeutic target in cancer. Expert Opin. Investig. Drugs 16 (2007) 451-465
8. Chaplin D.J., et al. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer Suppl. 27 (1996) S86-S88
9. Pettit G.R., et al. Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod. 50 (1987) 386-391
10. Dark G.G., et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57 (1997) 1829-1834
11. Tozer G.M., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59 (1999) 1626-1634
12. Pettit G.R., et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 10 (1995) 299-309
13. Tozer G.M., et al. Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61 (2001) 6413-6422
14. Prise V.E., et al. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21 (2002) 717-726
15. Hill S.A., et al. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 22 (2002) 1453-1458
16. Folkes L.K., et al. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem. Res. Toxicol. 20 (2007) 1885-1894
17. Hori K., and Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br. J. Cancer 89 (2003) 1334-1344
18. Soltau J., and Drevs J. ZD-6126 AstraZeneca. IDrugs 7 (2004) 380-387
19. Li L., et al. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 899-903
20. Nelkin B.D., and Ball D.W. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol. Rep. 8 (2001) 157-160
21. Horsman M.R., and Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 66 (2006) 11520-11539
22. Pedley R.B., et al. Synergy between vascular targeting agents and antibody-directed therapy. Int. J. Radiat. Oncol. 54 (2002) 1524-1531
23. Shaked Y., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
24. Dowlati A., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62 (2002) 3408-3416
25. Rustin G.J., et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21 (2003) 2815-2822
26. Galbraith S.M., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21 (2003) 2831-2842
27. Patterson D.M., and Rustin G.J.S. Vascular damaging agents. Clin. Oncol. 19 (2007) 443-456
28. Hill S., et al. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur. J. Cancer Clin. Oncol. 25 (1989) 1419-1424
29. Baguley B.C. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 4 (2003) 141-148
30. Ching L.M., et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 59 (1999) 3304-3307
31. Zhao L., et al. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer 87 (2002) 465-470
32. Siim B.G., et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol. 51 (2003) 43-52
33. Wilson W.R., et al. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 905-908
34. Jameson M.B., et al. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer Chemother. Pharmacol. 59 (2007) 681-687
35. McKeage M.J. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin. Investig. Drugs 17 (2008) 23-29
36. Galbraith S.M., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol. 20 (2002) 3826-3840
37. Rustin G.J., et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br. J. Cancer 88 (2003) 1160-1167
38. Kanthou C., and Tozer G.M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99 (2002) 2060-2069
39. Houle F., and Huot J. Dysregulation of the endothelial cellular response to oxidative stress in cancer. Mol. Carcinog. 45 (2006) 362-367
40. Petit I., et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111 (2008) 1951-1961
41. Kanthou C., and Tozer G.M. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin. Ther. Targets 11 (2007) 1443-1457
42. Bayless K.J., and Davis G.E. Microtubule depolymerisation rapidly collapses capillary tube networks in Vitro and angiogenic vessels in Vivo through the small GTPase Rho. J. Biol. Chem. 279 (2004) 11686-11695
43. Vincent L., et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Invest. 115 (2005) 2992-3006
44. Ahmed B., et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int. J. Cancer 105 (2003) 20-25
45. Zhao L., et al. Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest. New Drugs 25 (2007) 271-276
46. Watts M.E., et al. Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA. Br. J. Cancer Suppl. 27 (1996) S164-S167
47. Reyes-Aldasoro C.C., et al. Estimation of apparent tumour vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo. Microcirculation 15 (2007) 65-79
48. Zhao L., et al. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int. J. Cancer 116 (2005) 322-326
49. Wojciak-Stothard B., and Ridley A.J. Rho GTPases and the regulation of endothelial permeability. Vasc. Pharmacol. 39 (2002) 187-199
50. Bazzoni G., and Dejana E. Endothelial cell-to-cell junctions: molecular organisation and role in vascular homeostasis. Physiol. Rev. 84 (2004) 869-901
51. Ley C.D., et al. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 9 (2007) 108-112
52. Kanthou C., et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am. J. Pathol. 165 (2004) 1401-1411
53. Ching L.M., et al. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br. J. Cancer 90 (2004) 906-910
54. Brooks A.C., et al. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res. 23 (2003) 3199-3206
55. Ishizaki T., et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57 (2000) 976-983
56. Baluk P., et al. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15 (2005) 102-111
57. Beauregard D.A., et al. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. 61 (2001) 6811-6815
58. Eberhard A., et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60 (2000) 1388-1393
59. Honore S., et al. Understanding microtubule dynamics for improved cancer therapy. Cell Mol. Life Sci. 62 (2005) 3039-3056
60. Tozer G.M., et al. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br. J. Cancer 61 (1990) 250-257
61. Wojciak-Stothard B., et al. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 288 (2005) L749-L760
62. Tozer G., et al. Blood vessel maturation and response to vascular-disrupting therapy in single VEGF-A isoform-producing tumours. Cancer Res. 68 (2008) 2301-2311
63. Jockovich M.E., et al. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. Invest. Ophthalmol. Vis. Sci. 48 (2007) 2476-2482
64. Boucher Y., et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50 (1990) 4478-4484
65. Siemann D.W., and Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 60 (2004) 1233-1240
66. Dachs G.U., et al. Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 6 (2006) 280